STOCK TITAN

Adage Capital discloses 15,016,500-share (9.65%) passive WVE position on Schedule 13G

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of 15,016,500 ordinary shares of Wave Life Sciences, representing 9.65% of the class based on 155,562,665 ordinary shares outstanding as reported in the company's proxy. The filing is submitted on Schedule 13G (Amendment No. 4) and shows 0 sole voting or dispositive power and 15,016,500 shares of shared voting and dispositive power, held through Adage Capital Partners, L.P.

The filing includes a certification that the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer, indicating a stated passive investment intent.

Positive

  • Reporting Persons collectively beneficially own 15,016,500 shares, representing 9.65% of the outstanding ordinary shares as reported in the company's proxy
  • Filing is on Schedule 13G with a certification that the securities were acquired and are held in the ordinary course and not to influence control, indicating declared passive intent

Negative

  • Reporting Persons have 0 shares of sole voting or dispositive power, limiting any unilateral governance control
  • No disclosure of activist intent or plans to change control, which means the sizable stake does not come with an announced strategic or governance agenda

Insights

TL;DR: Adage holds a material 9.65% passive stake (15,016,500 shares) in WVE with shared voting and dispositive power.

The filing discloses a significant ownership position sized at 15,016,500 shares, equal to 9.65% of the reported 155,562,665 outstanding ordinary shares. Ownership is reported as shared voting and dispositive power with 0 shares of sole control, and the Schedule 13G includes a certification that the position is held in the ordinary course and not to influence control. From an investor perspective, this is a material passive stake that should be tracked for any future filings indicating a change in intent or level of control.

TL;DR: Schedule 13G filing indicates passive intent; shared voting/dispositive power is disclosed but no claim of sole control.

The reporting persons are identified as Adage Capital Management, L.P. and two individuals who act as managing members of the relevant Adage entities that hold the shares. The statement explicitly records shared voting and dispositive power over 15,016,500 shares and confirms the holdings were not acquired to change or influence issuer control. This filing therefore communicates a sizable, declaredly passive ownership position rather than an active governance or control campaign.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Adage Capital Management, L.P.
Signature:/s/ Robert Atchinson
Name/Title:By: Adage Capital Partners LLC, its General Partner, By: Robert Atchinson, its Managing Member
Date:08/12/2025
Robert Atchinson
Signature:/s/ Robert Atchinson
Name/Title:Robert Atchinson, individually
Date:08/12/2025
Phillip Gross
Signature:/s/ Phillip Gross
Name/Title:Phillip Gross, individually
Date:08/12/2025

FAQ

How many WVE shares does Adage Capital report owning?

Adage Capital and the reporting persons report beneficial ownership of 15,016,500 shares of Wave Life Sciences.

What percentage of WVE does the 15,016,500 shares represent?

The reported position represents 9.65% of the outstanding ordinary shares, based on 155,562,665 shares reported in the company's proxy.

Does Adage have sole voting or dispositive power over these WVE shares?

No. The filing reports 0 shares of sole voting power and 0 shares of sole dispositive power, with 15,016,500 shares reported as shared voting and dispositive power.

What type of SEC filing was submitted for the WVE position?

The position was disclosed on a Schedule 13G (Amendment No. 4) filing.

Did the filing state whether the stake was acquired to influence control of WVE?

Yes. The filing includes a certification that the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer.
Wave Life Scienc

NASDAQ:WVE

WVE Rankings

WVE Latest News

WVE Latest SEC Filings

WVE Stock Data

2.49B
157.87M
15.79%
86.89%
10.88%
Biotechnology
Pharmaceutical Preparations
Link
Singapore
SINGAPORE